Using live melanoma cell immunization and high-throughput screening (HTS) [1], we generated a novel neutralizing monoclonal antibody (mAb) directed against a melanoma cell-surface antigen, which we subsequently identified as the functional, glycosylated protein MUC18. The gene discussed is CD53; the disease is melanoma.